Form 4 for GYRE GYRE THERAPEUTICS, INC.

Accepted 2023-10-27 00:00:00 ET · period of report 2023-10-27 · accession 0001140361-23-050019 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-10-27	2023-10-27	GYRE	GNI Hong Kong Ltd	10%	J - Other	—	-5.37M	0	-100%	—
D	2023-10-27	2023-10-27	GYRE	GNI Hong Kong Ltd	10%	J - Other	—	-10.6K	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-10-27	J	D	5,371,304	—	0	D	—	—	(F1) Represents an internal transfer by the Reporting Person, a wholly-owned indirect subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability ("GNI Japan"), to GNI Japan, pursuant to the Share Purchase Agreement, dated as of October 27, 2023, by and between the Reporting Person and GNI Japan, in exchange for consideration of $46,624,376.
2	Derivative	Series X Convertible Preferred Stock	2023-10-27	J	D	10,577	—	0	D	— · — to —	105,770,000 Common Stock	(F2) Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the "Preferred Stock"), are convertible into shares of common stock of the Issuer at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).